Skip to Main Content
Table 2.

Characteristics of patients experiencing clinical benefit

Age/GenderTumor typeSites of metastatic diseasePrior chemotherapy in chronological orderBest ResponseTime to Progression (d)
55/M Hodgkin's disease Cervical, mediastinal, abdominopelvic nodes ABVD (epirubicin used; 6 cycles), DHAP (3 cycles) CR 748 
34/M Hodgkin's disease Lung, liver, pelvis ABVD (6 cycles), mini-BEAM, oral etoposide (2 cycles) CR 418 
24/F Hodgkin's disease Mediastinal adenopathy ABVD (6 cycles), DHAP (2 cycles), cyclophosphamide, carmustine, etoposide (1 cycle)* PR 749 
78/M Rectum Lung FUFA (17 cycles), irinotecan (4 cycles), CONT FU (3 cycles) PR 358 
56/F Endometrium Lung, liver None PR 325 
69/M Pancreas Liver None PR 253 
59/F Breast Lung, cervical nodes Paclitaxel (2 cycles), FAC (6 cycles), MMM (5 cycles) SD 391 
79/F Liver Liver, kidney Doxorubicin (6 cycles) SD 344 
56/F Cholangiocarcinoma Liver, kidney ECF (6 cycles) SD 227 
69/F Pancreas Locally advanced adenocarcinoma None SD 226 
63/F Leiomyosarcoma Liver, abdominal mass, bone, skin Doxorubicin (1 cycle) SD 211 
71/F Endometrium Lung None SD 209 
70/M Colon (ascending) Liver IFL (2 cycles) SD 198 
53/M Malignant melanoma Liver None SD 192 
Age/GenderTumor typeSites of metastatic diseasePrior chemotherapy in chronological orderBest ResponseTime to Progression (d)
55/M Hodgkin's disease Cervical, mediastinal, abdominopelvic nodes ABVD (epirubicin used; 6 cycles), DHAP (3 cycles) CR 748 
34/M Hodgkin's disease Lung, liver, pelvis ABVD (6 cycles), mini-BEAM, oral etoposide (2 cycles) CR 418 
24/F Hodgkin's disease Mediastinal adenopathy ABVD (6 cycles), DHAP (2 cycles), cyclophosphamide, carmustine, etoposide (1 cycle)* PR 749 
78/M Rectum Lung FUFA (17 cycles), irinotecan (4 cycles), CONT FU (3 cycles) PR 358 
56/F Endometrium Lung, liver None PR 325 
69/M Pancreas Liver None PR 253 
59/F Breast Lung, cervical nodes Paclitaxel (2 cycles), FAC (6 cycles), MMM (5 cycles) SD 391 
79/F Liver Liver, kidney Doxorubicin (6 cycles) SD 344 
56/F Cholangiocarcinoma Liver, kidney ECF (6 cycles) SD 227 
69/F Pancreas Locally advanced adenocarcinoma None SD 226 
63/F Leiomyosarcoma Liver, abdominal mass, bone, skin Doxorubicin (1 cycle) SD 211 
71/F Endometrium Lung None SD 209 
70/M Colon (ascending) Liver IFL (2 cycles) SD 198 
53/M Malignant melanoma Liver None SD 192 

Abbreviations: CR, complete response; PR, partial response; SD, stable disease.

*

Given as high dose therapy with autologous stem cell rescue.

Close Modal

or Create an Account

Close Modal
Close Modal